Recursion Pharmaceuticals Stock Alpha and Beta Analysis
| RXRX Stock | USD 7.07 0.69 10.82% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Recursion Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Recursion Pharmaceuticals over a specified time horizon. Remember, high Recursion Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Recursion Pharmaceuticals' market risk premium analysis include:
Beta 2.3 | Alpha (0.26) | Risk 4.05 | Sharpe Ratio 0.0787 | Expected Return 0.32 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Recursion |
Recursion Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Recursion Pharmaceuticals market risk premium is the additional return an investor will receive from holding Recursion Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Recursion Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Recursion Pharmaceuticals' performance over market.| α | -0.26 | β | 2.30 |
Recursion Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Recursion Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Recursion Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Recursion Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Recursion Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Recursion Pharmaceuticals shares will generate the highest return on investment. By understating and applying Recursion Pharmaceuticals stock market price indicators, traders can identify Recursion Pharmaceuticals position entry and exit signals to maximize returns.
Recursion Pharmaceuticals Return and Market Media
The median price of Recursion Pharmaceuticals for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 6.61 with a coefficient of variation of 6.93. The daily time series for the period is distributed with a sample standard deviation of 0.46, arithmetic mean of 6.58, and mean deviation of 0.37. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 375 shares by Michael Secora of Recursion Pharmaceuticals at 2.22 subject to Rule 16b-3 | 09/10/2024 |
2 | Disposition of 11447 shares by Blake Borgeson of Recursion Pharmaceuticals at 6.8431 subject to Rule 16b-3 | 09/17/2024 |
3 | Disposition of tradable shares by Marriott Tina of Recursion Pharmaceuticals at 1.06 subject to Rule 16b-3 | 09/26/2024 |
4 | Disposition of 50000 shares by Christopher Gibson of Recursion Pharmaceuticals subject to Rule 16b-3 | 10/21/2024 |
5 | Recursion Pharmaceuticals Beats Stock Market Upswing What Investors Need to Know | 10/24/2024 |
6 | Disposition of 11447 shares by Blake Borgeson of Recursion Pharmaceuticals at 6.7202 subject to Rule 16b-3 | 10/29/2024 |
7 | Recursion Pharmaceuticals Inc Q3 2024 Earnings Report Preview What To Expect | 11/05/2024 |
8 | Recursion Pharmaceuticals Q3 Earnings Snapshot | 11/06/2024 |
9 | Recursion Pharmaceuticals Announces First Amendment to Transaction Agreement with ExscientiaSalt Lake City, UT Recursion Pharmaceuticals, Inc. , a Delaware corp... | 11/12/2024 |
10 | FMR LLCs Strategic Acquisition in Recursion Pharmaceuticals Inc | 11/13/2024 |
11 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 7.35 subject to Rule 16b-3 | 11/14/2024 |
12 | Insider Sale Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc | 11/15/2024 |
13 | Recursion Pharmaceuticals Hits New 1-Year Low - Heres What Happened - MarketBeat | 11/19/2024 |
14 | 2 Innovative Stocks That Could Deliver Outsize Returns | 11/22/2024 |
15 | Jim Cramer Reddit Is Fabulous, Dow Is A Tough One | 11/27/2024 |
About Recursion Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Recursion or other stocks. Alpha measures the amount that position in Recursion Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 3.23 | 10.53 | 10.77 | 10.23 | Days Of Inventory On Hand | 62.22 | 9.68 | 11.13 | 10.57 |
Recursion Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Recursion Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Recursion Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Recursion Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Recursion Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Recursion Pharmaceuticals' management manipulating its earnings.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Recursion Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.